[go: up one dir, main page]

CU23504A1 - Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas - Google Patents

Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas

Info

Publication number
CU23504A1
CU23504A1 CU20040207A CU20040207A CU23504A1 CU 23504 A1 CU23504 A1 CU 23504A1 CU 20040207 A CU20040207 A CU 20040207A CU 20040207 A CU20040207 A CU 20040207A CU 23504 A1 CU23504 A1 CU 23504A1
Authority
CU
Cuba
Prior art keywords
peptides
pharmaceutical compositions
hsp60
derivatives
rheumatoid arthritis
Prior art date
Application number
CU20040207A
Other languages
English (en)
Inventor
Diaz Carelia Cosme
Alba Jose Suarez
Bonachea Ariel Vazquez
Garcia Nelson J Merino
Garcia Ariadna Hernandez
Betancourt Ariana Barbera
Perez Norailys Lorenzo
Marin Nelia Lopez
Horta Maria Del Carmen Dominguez
Palomares Gabriel Ramon Padron
Cordova Vivian Morera
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20040207A priority Critical patent/CU23504A1/es
Priority to ARP050103950A priority patent/AR051928A1/es
Priority to ES10189769.2T priority patent/ES2445707T3/es
Priority to BR122018077204A priority patent/BR122018077204B8/pt
Priority to PCT/CU2005/000008 priority patent/WO2006032216A2/es
Priority to KR1020077008682A priority patent/KR101054332B1/ko
Priority to MX2007003624A priority patent/MX2007003624A/es
Priority to KR1020107001135A priority patent/KR101035283B1/ko
Priority to US11/663,603 priority patent/US8383771B2/en
Priority to EP05794474A priority patent/EP1803732B1/en
Priority to CA2797769A priority patent/CA2797769C/en
Priority to CN2010100038161A priority patent/CN101935345B/zh
Priority to EP10189769.2A priority patent/EP2371847B1/en
Priority to ES05794474T priority patent/ES2386498T3/es
Priority to AT05794474T priority patent/ATE546462T1/de
Priority to BRPI0515893A priority patent/BRPI0515893B8/pt
Priority to DK10189769.2T priority patent/DK2371847T3/da
Priority to DK05794474.6T priority patent/DK1803732T3/da
Priority to JP2007532752A priority patent/JP4755649B2/ja
Priority to CA2581110A priority patent/CA2581110C/en
Priority to AU2005287757A priority patent/AU2005287757B2/en
Priority to CN2005800403891A priority patent/CN101065398B/zh
Priority to RU2007115411/04A priority patent/RU2361877C2/ru
Priority to ZA200702938A priority patent/ZA200702938B/xx
Priority to ARP090105137A priority patent/AR074924A2/es
Priority to US12/649,687 priority patent/US8324164B2/en
Publication of CU23504A1 publication Critical patent/CU23504A1/es
Priority to AU2010219312A priority patent/AU2010219312B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Péptidos de la proteína humana de estrés térmico de 60 KDa que constituyen epitopes para células T, asi como péptidos derivados de ellos, los cuales están modificados en los sitios de contacto con la molécula MHC, útiles para inducir mecanismos de tolerancia periférica, en particular mecanismos inductores de anergia o mediados por clones de células T regulatorias en pacientes con Artritis Reumatoide. La invención también refiere composiciones farmacéuticas que comprenden tales péptidos para tratamiento de la Artritis Reumatoide.
CU20040207A 2004-09-24 2004-09-24 Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas CU23504A1 (es)

Priority Applications (27)

Application Number Priority Date Filing Date Title
CU20040207A CU23504A1 (es) 2004-09-24 2004-09-24 Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
ARP050103950A AR051928A1 (es) 2004-09-24 2005-09-21 Peptidos y derivados tipo apl de la hsp60 y composiciones farmaceuticas
ES05794474T ES2386498T3 (es) 2004-09-24 2005-09-22 Péptidos y derivados tipo APL de Hsp60 y composiciones farmacéuticas
BRPI0515893A BRPI0515893B8 (pt) 2004-09-24 2005-09-22 peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica.
PCT/CU2005/000008 WO2006032216A2 (es) 2004-09-24 2005-09-22 Peptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
KR1020077008682A KR101054332B1 (ko) 2004-09-24 2005-09-22 Ｈｓｐ60의 펩티드 및 이들의 유도형 ａｐｌ 및 약학적조성물
MX2007003624A MX2007003624A (es) 2004-09-24 2005-09-22 Peptidos y derivados tipo peptido ligando alterado de la hsp60 y composiciones farmaceuticas.
KR1020107001135A KR101035283B1 (ko) 2004-09-24 2005-09-22 Ｈｓｐ60의 펩티드 및 이들의 유도형 ａｐｌ 및 약학적 조성물
US11/663,603 US8383771B2 (en) 2004-09-24 2005-09-22 Altered peptide ligand derived from HSP60 and pharmaceutical compositions
EP05794474A EP1803732B1 (en) 2004-09-24 2005-09-22 Peptides and apl-type derivatives of hsp60 and pharmaceutical compositions
CA2797769A CA2797769C (en) 2004-09-24 2005-09-22 Peptides and apl-type derivatives of hsp60 and pharmaceutical compositions
CN2010100038161A CN101935345B (zh) 2004-09-24 2005-09-22 Hsp60的肽和apl型衍生物及药物组合物
EP10189769.2A EP2371847B1 (en) 2004-09-24 2005-09-22 Peptides and their derived type APL of the HSP60 and pharmaceutical compositions
ES10189769.2T ES2445707T3 (es) 2004-09-24 2005-09-22 Péptidos y derivados tipo APL de Hsp60 y composiciones farmacéuticas
AT05794474T ATE546462T1 (de) 2004-09-24 2005-09-22 Peptide und derivate vom apl-typ von hsp60 und pharmazeutische zusammensetzungen
BR122018077204A BR122018077204B8 (pt) 2004-09-24 2005-09-22 peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica
DK10189769.2T DK2371847T3 (da) 2004-09-24 2005-09-22 Peptider og deres afledte type APL af HSP60 og farmaceutiske sammensætninger
DK05794474.6T DK1803732T3 (da) 2004-09-24 2005-09-22 Peptider og derivater af APL-TYPE af HSP60 og famaceutiske sammensætninger
JP2007532752A JP4755649B2 (ja) 2004-09-24 2005-09-22 Ｈｓｐ６０のペプチド及びａｐｌ型誘導体並びに医薬組成物
CA2581110A CA2581110C (en) 2004-09-24 2005-09-22 Peptides and apl-type derivatives of hsp60 and pharmaceutical compositions
AU2005287757A AU2005287757B2 (en) 2004-09-24 2005-09-22 Peptides and APL-type derivatives of Hsp60 and pharmaceutical compositions
CN2005800403891A CN101065398B (zh) 2004-09-24 2005-09-22 Hsp60的肽和apl型衍生物及药物组合物
RU2007115411/04A RU2361877C2 (ru) 2004-09-24 2005-09-22 Пептиды hsp60 и их apl-производные и фармацевтические композиции
ZA200702938A ZA200702938B (en) 2004-09-24 2007-04-10 Peptides and APL-type derivatives of Hsp60 and pharmaceutical compositions
ARP090105137A AR074924A2 (es) 2004-09-24 2009-12-28 Peptidos y derivados tipo peptido ligando alterado (apl) de la hsp60 y composiciones farmaceuticas
US12/649,687 US8324164B2 (en) 2004-09-24 2009-12-30 Peptides and altered peptide ligands derived from HSP60 and pharmaceutical compositions
AU2010219312A AU2010219312B2 (en) 2004-09-24 2010-09-06 Peptides and APL-type derivatives of HSP60 and pharmaceutical compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20040207A CU23504A1 (es) 2004-09-24 2004-09-24 Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas

Publications (1)

Publication Number Publication Date
CU23504A1 true CU23504A1 (es) 2010-04-13

Family

ID=40273413

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20040207A CU23504A1 (es) 2004-09-24 2004-09-24 Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas

Country Status (17)

Country Link
US (2) US8383771B2 (es)
EP (2) EP2371847B1 (es)
JP (1) JP4755649B2 (es)
KR (2) KR101035283B1 (es)
CN (2) CN101935345B (es)
AR (2) AR051928A1 (es)
AT (1) ATE546462T1 (es)
AU (2) AU2005287757B2 (es)
BR (2) BR122018077204B8 (es)
CA (2) CA2797769C (es)
CU (1) CU23504A1 (es)
DK (2) DK1803732T3 (es)
ES (2) ES2445707T3 (es)
MX (1) MX2007003624A (es)
RU (1) RU2361877C2 (es)
WO (1) WO2006032216A2 (es)
ZA (1) ZA200702938B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2423221B1 (en) 2007-01-30 2015-04-29 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
CU23701A1 (es) * 2008-12-29 2011-09-21 Ct Ingenieria Genetica Biotech Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i
EP3366308A1 (en) * 2009-09-06 2018-08-29 Protab Ltd. Humanized antibodies specific for hsp65-derived peptide-6 methods and uses thereof
WO2011059758A2 (en) * 2009-10-28 2011-05-19 Argentis Pharmaceuticals, Llc Apls for treating arthritis
CU24508B1 (es) * 2017-12-29 2021-04-07 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica que comprende péptido tipo apl
CU20200026A7 (es) * 2020-04-13 2021-11-04 Ct Ingenieria Genetica Biotecnologia Péptido para el tratamiento del síndrome de la tormenta de citocinas
CN111870697B (zh) * 2020-09-18 2022-09-09 山东鲁抗医药股份有限公司 糖类物质在提高apl型衍生肽稳定性中的应用和冻干组合物
KR102333645B1 (ko) 2021-07-27 2021-12-02 (주)문화전기 각도조절이 용이한 엘이디조명시스템
CN117883547A (zh) * 2021-07-30 2024-04-16 河北菲尼斯生物技术有限公司 Se-dr亲和肽在制备治疗风湿疾病的药物中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8701163A (nl) 1986-09-09 1988-04-05 Nederlanden Staat Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.
NL8703107A (nl) 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
US5773570A (en) 1994-05-20 1998-06-30 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
GB9419553D0 (en) 1994-09-27 1994-11-16 Univ Bristol Polypeptides and their use in the treatment of auto-immune disease
US6180103B1 (en) 1994-12-21 2001-01-30 Yeda Research And Development Co., Ltd. Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
GB9519737D0 (en) 1995-09-27 1995-11-29 Peptide Therapeutics Ltd Polypeptides and their use in treatment and prophylaxis of auto-immune
TW575583B (en) * 1996-04-24 2004-02-11 Akzo Nobel Nv Novel peptides suitable for use in antigen specific immunosuppressive therapy
US5993803A (en) 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
GB9911772D0 (en) 1999-05-21 1999-07-21 Semmelweis University Of Medic Diagnosis and treatment of atherosclerosis
US20020169302A1 (en) * 1999-08-23 2002-11-14 Genesis Research And Development Corp. Ltd. Compositions isolated from bovine mammary gland and methods for their use
NZ519348A (en) * 1999-12-15 2006-04-28 Develogen Israel Ltd Fragments and antagonists of heat shock protein 60
US7534419B2 (en) 2001-01-19 2009-05-19 Depuy Mitek, Inc. Methods of diagnosis and treatment of osteoporosis

Also Published As

Publication number Publication date
CN101065398A (zh) 2007-10-31
BRPI0515893A (pt) 2008-08-12
AU2005287757A1 (en) 2006-03-30
BR122018077204B8 (pt) 2021-07-27
EP2371847A1 (en) 2011-10-05
MX2007003624A (es) 2007-06-13
JP2008514553A (ja) 2008-05-08
CN101935345B (zh) 2013-12-11
CA2581110C (en) 2013-04-02
JP4755649B2 (ja) 2011-08-24
BRPI0515893B8 (pt) 2021-05-25
AU2005287757B2 (en) 2010-07-29
RU2361877C2 (ru) 2009-07-20
CN101935345A (zh) 2011-01-05
BR122018077204B1 (pt) 2020-01-28
DK2371847T3 (da) 2014-02-03
US20090171069A1 (en) 2009-07-02
US20100144642A1 (en) 2010-06-10
KR20070073787A (ko) 2007-07-10
ATE546462T1 (de) 2012-03-15
DK1803732T3 (da) 2012-05-29
KR20100028645A (ko) 2010-03-12
EP1803732B1 (en) 2012-02-22
AR074924A2 (es) 2011-02-23
AR051928A1 (es) 2007-02-21
BRPI0515893A8 (pt) 2019-01-02
ZA200702938B (en) 2008-08-27
EP2371847B1 (en) 2013-11-20
BRPI0515893B1 (pt) 2020-09-15
KR101054332B1 (ko) 2011-08-04
EP1803732A2 (en) 2007-07-04
CA2797769A1 (en) 2006-03-30
US8324164B2 (en) 2012-12-04
RU2007115411A (ru) 2008-10-27
CN101065398B (zh) 2012-12-19
AU2010219312A1 (en) 2010-09-23
WO2006032216A2 (es) 2006-03-30
WO2006032216A3 (es) 2007-05-18
US8383771B2 (en) 2013-02-26
ES2386498T3 (es) 2012-08-22
ES2445707T3 (es) 2014-03-04
CA2797769C (en) 2015-09-15
AU2010219312B2 (en) 2011-10-06
KR101035283B1 (ko) 2011-05-18
CA2581110A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
EA201270713A1 (ru) Белки на основе фибронектина с каркасными доменами, которые связывают ил-23
DOP2010000150A (es) Anticuerpos antimesotelina y usos de los mismos
PE20081501A1 (es) Polipeptidos heterologos il-17a/f y usos terapeuticos de los mismos
EA201892619A1 (ru) Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
PE20200152A1 (es) Receptores de union a antigeno mejorados
MX2019006727A (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza.
EA201300896A1 (ru) Мутантные полипептиды интерлейкина-2
AR074924A2 (es) Peptidos y derivados tipo peptido ligando alterado (apl) de la hsp60 y composiciones farmaceuticas
NO20092121L (no) Humaniserte anti-faktor D-antistoffer og anvendelser derav
CR20110639A (es) Mutantes fgf21 y usos de los mismos
MX2022015847A (es) Proteinas de union a cd123 y composiciones y metodos relacionados.
CL2018000537A1 (es) Anticuerpo anti-factor d del complemento; polinucleótido codificante; vector que comprende dicho polinucleótido; célula húesped que comprende dicho vector; método de fabricación de anticuerpo; composición farmacéutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares (divisional de cl 1001-2009).
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
EA201591766A1 (ru) Мутеины интерлейкина-2 для экспансии регуляторных т-клеток
EA201000238A1 (ru) Антигенсвязывающие белки для il-18 рецептора и их применение
CL2011001578A1 (es) Anticuerpo que inhibe selectivamente al receptor del peptido relacionado al gen de la calcitonina ( cgrp r) humano; polinucleotido que lo codifica; vector; celula; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar un medicamento para tratar una condicion asociada con cgrp r en un paciente, como migraña.
ES2353814T3 (es) Proteinas n-glicosiladas recombinantes de celulas procariotas.
UY30430A1 (es) Compuestos
MX2016009687A (es) Proteinas de fusion de interleucina-2 y usos de las mismas.
AR071874A1 (es) Proteinas de dominio de armazon basadas en fibronectina multivalentes
IN2012DN02981A (es)
PE20170906A1 (es) Alfa-glucosidasa acida muy potente con hidratos de carbono potenciados
BR112013002831A2 (pt) anticorpos direcionados contra a il-17
MX360085B (es) Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.
BRPI0508670A (pt) proteìnas de buganina modificada, citotoxinas e métodos e usos delas

Legal Events

Date Code Title Description
FG Grant of patent